HighTower Advisors’s PDL BioPharma, Inc. PDLI Stock Holding History

HighTower Advisors’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-10,685	Closed	-$36K	–	2448
2017 Q3	$36K	Buy	+10,685	New	+$29.7K	﹤0.01%	2101
2017 Q1	–	Sell	-13,887	Closed	-$29K	–	2226
2016 Q4	$29K	Buy	+13,887	New	+$38.7K	﹤0.01%	1848
2015 Q1	–	Sell	-195,848	Closed	-$1.51M	–	1770
2014 Q4	$1.51M	Buy	195,848 +4,125	+2%	+$32.6K	0.02%	671
2014 Q3	$1.43M	Sell	191,723 -82,638	-30%	-$767K	0.02%	656
2014 Q2	$2.66M	Sell	274,361 -14,707	-5%	-$131K	0.05%	475
2014 Q1	$2.4M	Buy	289,068 +159,438	+123%	+$1.37M	0.05%	455
2013 Q4	$1.09M	Buy	129,630 +43,170	+50%	+$364K	0.02%	668
2013 Q3	$962K	Buy	+86,460	New	+$695K	0.02%	633

Other funds holding PDLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

HighTower Advisors's PDLI Position: Q4 2017 in Review

HighTower Advisors sold out of PDL BioPharma, Inc. (PDLI) in Q4 2017, closing a stake of 10,685 shares — an estimated $36K sold.

HighTower Advisors first reported a position in PDLI in Q3 2013 and held it in 8 quarters. The position peaked at $2.66M in Q2 2014. 187 funds tracked by Wall St. Rank hold PDLI as of Q4 2017.

HighTower Advisors reported no remaining PDL BioPharma, Inc. position as of Q4 2017 after selling out during the quarter.
HighTower Advisors sold 10,685 PDL BioPharma, Inc. shares in Q4 2017, an estimated $36K.
HighTower Advisors first reported a position in PDL BioPharma, Inc. in Q3 2013 and held it in 8 quarters.
HighTower Advisors's PDL BioPharma, Inc. position peaked at $2.66M in Q2 2014.
187 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2017.

Based on HighTower Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.